NASDAQ$PGEN

Precigen Inc · Q3 2022 earnings

Q3 2022 earnings · · Investor relations

Briefing

Precigen's financial performance increased due to collaboration and licensing revenues, offset by decreased product and service revenues. R&D expenses remained relatively stable, while SG&A expenses decreased. The company retired a significant amount of convertible notes, improving its financial position.

Precigen reported increased total revenues driven by collaboration and licensing agreements, offset by a decrease in product and service revenues. The company's loss from continuing operations improved compared to the prior year. Precigen also retired $144.0 million of convertible notes, strengthening its financial position.

  • Total revenues increased by $13.4 million, or greater than 200%, compared to the third quarter of 2021.
  • Collaboration and licensing revenues increased by $14.5 million due to revenue recognition from previously deferred agreements.
  • The company retired $144.0 million of outstanding convertible notes due in July 2023, resulting in $5.4 million in savings.
  • Cash, cash equivalents, short-term investments and restricted cash totaled $153.8 million as of September 30, 2022

Headline financials

Total Revenue

$16.7M

Previous: $21.6M-22.4%
EPS (adj)

-$0.04

Previous: -$0.15+73.3%
Capital Expenditures

-$4.87M

Previous: -$4.47M-8.9%
Free Cash Flow

$82.5M

Previous: -$34.2M+341.0%
Net Income

$87.4M

Previous: -$29.8M+393.6%
Operating Income

-$4.28M

Previous: -$5.49M+22.1%
Gross Profit

$15.1M

Previous: $6.11M+147.8%
Cash & Equivalents

$9.07M

Previous: $41.7M-78.3%
Total Assets

$259M

Previous: $377M-31.2%
Stock-Based Comp

$2.13M

Previous: $2.49M-14.7%

Revenue & EPS history

Precigen · Revenue · Quarterly

$16.7M

Q3 2022-22.4%vs Q3 2021
Beat estimate in 5 of 14 quarters(36%)
ActualEstimate

Revenue by segment

Precigen · $18.4M total across 3 segments · Q4 2020

  • Service revenue
    $14.3M+18.1%
  • Product revenue
    $3.95M-25.4%
  • Collab & licensing
    $148K-44.6%

Forward guidance

Precigen believes its cash runway is sufficient to advance its clinical priorities into Q4 2023.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 18 quarterly earnings reports · overlaid with Q3 2022

Historical avgQ3 2022

+0.4%

Avg return

Earnings day

+1.6%

Avg return

5 days after

+1.4%

Avg return

30 days after

50%

26 / 52 earnings

Positive

+31.0%

Q2 2023

Best reaction

-38.9%

Q4 2018

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q4 2025
Q1 2026+1.7%-0.2%
Q3 2025+25.6%+9.3%-4.4%
Q2 2025+6.1%+63.9%+110.6%
Q1 2025-2.8%-5.7%+0.7%
Q4 2024+0.6%-4.5%-22.3%
Q3 2024-10.4%-13.0%-26.1%
Q1 2024+6.7%+2.2%+25.9%
Q4 2023+3.6%+0.7%-5.0%
Q3 2023-13.5%-19.8%-6.3%
Q2 2023+31.0%+43.1%+39.7%
Q1 2023-9.5%-4.0%-6.3%
Q4 2022+16.4%-6.0%-15.5%
Q3 2022+11.2%+18.1%-2.5%
Q2 2022+11.6%+14.5%+11.1%
Q1 2022+3.2%+8.0%+23.2%
Q4 2021-1.3%-10.2%-6.2%
Q3 2021-7.1%-11.8%-33.3%
Q2 2021+8.6%+10.4%+10.6%
Q1 2021-0.2%+5.7%+9.5%
Q4 2020+1.7%+0.1%-18.4%
Q3 2020+22.2%+20.4%+69.7%
Q2 2020-5.7%-8.8%-1.0%
Q1 2020-5.9%-4.2%-4.7%
Q4 2019-14.5%-19.0%-27.4%
Q3 2019-1.1%+2.0%+6.3%
Q2 2019-7.2%-10.3%-23.4%
Q1 2019-1.1%+0.7%+22.2%
Q4 2018-38.9%-39.4%-36.5%
Q3 2018-19.3%-24.4%-32.1%
Q2 2018-5.7%-4.6%-2.9%
Q1 2018-19.5%-13.0%-9.3%
Q4 2017+23.6%+20.9%+17.7%
Q3 2017-25.3%-19.7%-15.9%
Q2 2017-5.2%-4.0%-15.0%
Q1 2017+21.5%+32.0%+15.0%
Q4 2016+5.8%+2.1%-11.0%
Q3 2016+14.1%+24.0%+15.7%
Q2 2016+3.3%+4.5%+0.9%
Q1 2016-5.1%
Q4 2015-0.1%
Q3 2015+9.7%
Q2 2015-17.8%
Q1 2015+3.2%
Q4 2014+17.3%
Q3 2014-3.9%
Q2 2014-2.9%
Q1 2013+2.9%
Q1 2014-11.7%
Q4 2013+5.5%
Q3 2012+3.6%
Q3 2013+3.6%
Q2 2013-7.8%
Q4 2012
Q2 2012
Q1 2012

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro